ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Annika Gustafsson Asting, Kristina K. Lagerstedt, Erik Kristiansson, Christina Lönnroth, Marianne Andersson, Elham Rekabdar, Elisabeth Hansson, Ulf Kressner, Fredrik Enlund, Kent Lundholm, 1 1
Background: Sporadic colorectal tumors probably carry genetic alterations that may be related to familiar clusters according to risk loci visualized by SNP arrays on normal tissues. The aim of the present study was therefore to search for DNA regions (copy nu…
Benedetta Pesi, Luca Moraldi, Daniela Zambonin, Francesco Giudici, Tiziana Cavalli, Rami Addasi, Francesca Leo, Stefano Scaringi, Giacomo Batignani
Background: Hepatocellular carcinoma (HCC) is one of the most common cancer in the world. Liver resection (LR) is the most used therapy in well compensated liver cirrhosis and maybe used as a first-line treatment. Aim of the study is to evaluate survival rate…
Maria Varela, Olegario Castaño-Fernández, Marcelo Garrido, Lorena Blanco-García, Pablo Martínez-Camblor, Alicia Mesa-Álvarez, Carmen Navascués, Valle Cadahía-Rodrigo, Rafael Menéndez de Llano, Ramon Pérez-Álvarez, Maria Luisa González-Diéguez, Manuel Rodríguez, 1 1
Background: The standard therapy in advanced hepatocellular carcinoma (HCC) is sorafenib (SOR), which has the inconvenience of toxicity and discontinuation. Patient selection and the use of early markers are critical for optimizing the potential benefit of SO…
Consolato Sergi, 1 1
Fibrolamellar carcinoma (FL-HCC) is overall a quite rare variant of hepatocellular carcinoma (HCC) that is intriguing and poorly understood at same time. In humans, it affects essentially the young population (children and young adults) in the peculiar absenc…
Anne H. O’Donnell, John R. Edwards, Robert A. Rollins, Nathan D. Vander Kraats, Tao Su, Hanina H. Hibshoosh, Timothy H. Bestor, 1 1, 1 1
Promoter silencing by ectopic de novo methylation of tumor suppressor genes has been proposed as comparable or equivalent to inactivating mutations as a factor in carcinogenesis. However, this hypotheses had not previously been tested by high resolution, high…
Shadi Alkhayyat, Hind I. Fallatah, Hisham O. Akbar, Mahmoud S. Al Ahwal, Waleed S. Al Ghamdi
Background: With 748,300 new cases diagnosed every year, hepatocellular carcinoma (HCC) is the 5 th and the 7 th most common cancer among males and females, respectively, and causes 7% of all cancer-related deaths. HCC represents more than 90% of primary live…
Heather M. Calderone, Akshita Dutta, Lauren Smith, Alexandra Eckardt, Ping Zhao, Giselle Saulnier Sholler, 1 1
Background: Neuroblastoma exhibits a high incidence of chromosomal translocations, the most common being the gain of a portion of the long arm of chromosome 17. This region includes the gene BIRC5/survivin, which is highly upregulated in neuroblastoma and cor…
Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Sheldon Brookman
Colorectal cancer (CRC) is the second leading cause of cancer death related mortality with 1.2 million new cases diagnosed annually worldwide. Despite remarkable advances in the treatment of resectable CRC, advanced disease that recurs following initial two l…
Javier Adur, Mariana Bianchi, Vitor B. Pelegati, Silvia Viale, María F. Izaguirre, Hernandes F. Carvalho, Carlos L. Cesar, Víctor H. Casco, 1 1, 1 1
Combined multimodal nonlinear optical (NLO) microscopies were used to detect and quantify morphological changes associated with stroma and epithelial transformation in colon cancer. Our findings provide complementary information about tissue microstructure, d…
Donald A. Ross, Shao Tao, Sakir Gultekin, Amy M. Ross
Grade II oligodendrogliomas are rare and slow growing tumors, making long-term follow up difficult, but necessary for better understanding. In this retrospective study a review of all grade II oligodendrogliomas encountered in the last 20 years at one institu…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).